NASDAQ OMX

Abiomed Announces Q4 FY 2016 Revenue of $94.0 Million, Up 39% Over Prior Year

3.5.2016 13:00 | NASDAQ OMX

Del

DANVERS, Mass., 2016-05-03 13:00 CEST (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2016 revenue of $94.0 million, an increase of 39% compared to revenue of $67.6 million for the same period of fiscal 2015.  For fiscal year 2016, total revenue was $329.5 million, up 43% compared to revenue of $230.3 million in fiscal year 2015. This revenue exceeds the third quarter upgraded fiscal year guidance of $326 million.

Fourth quarter fiscal 2016 GAAP net income was $11.0 million or $0.24 per diluted share. For the full fiscal year, GAAP net income was $38.1 million or $0.85 per diluted share.

Financial and operating highlights during the fourth quarter of fiscal 2016 include:

  • Fiscal fourth quarter worldwide Impella® heart pump revenue totaled $88.6 million, an increase of 40% compared to revenue of $63.4 million during the same period of the prior fiscal year.  Full year worldwide Impella revenue totaled $310.1 million, up 46% compared to $212.7 million for fiscal 2015. 
     
  • U.S. Impella heart pump revenue grew 42% to $81.8 million from $57.7 million in the prior fiscal year with U.S. patient usage of the Impella heart pumps up 45%.  Full year U.S. Impella revenue totaled $287.2 million, up 50% compared to $191.5 million in the prior fiscal year.
     
  • The installed base for Impella 2.5™ heart pumps grew by an additional 19 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,039 sites.  As part of Abiomed's continued Impella CP® heart pump launch, 38 new U.S. hospitals purchased Impella CP, bringing the total number to 826 sites.  
     
  • The installed base for Impella RP® heart pumps grew by an additional 9 hospitals, bringing the total number to 80 sites.
     
  • Gross margin for fiscal fourth quarter 2016 was 84.4% compared to 84.0% in the fourth quarter of fiscal 2015.  For the full fiscal year, gross margin was 84.7% compared to 82.7% in the prior year.
     
  • Income from operations for the fourth quarter of fiscal 2016 was $19.8 million, or 21%  operating margin, compared to $12.4 million, or 18.3% of revenue in the prior year period. For the full fiscal year, income from operations was $65.1 million, or 19.8% of revenue, compared to $28.7 million, or 12.4% of revenue in the prior year.
     
  • The Company generated $16.9 million in cash, cash equivalents and marketable securities, totaling $213.1 million as of March 31, 2016, compared to $196.2 million at December 31, 2015. The Company currently has no debt. 
     
  • In the prior year, GAAP net income included an income tax benefit of $86.5 million largely due to the release of the valuation allowance on most of Abiomed’s deferred tax assets. The release of the valuation allowance was a one-time accounting adjustment in the prior year. As such, fourth quarter fiscal 2015 GAAP net income was $98.9 million ($86.5 million driven by one-time adjustment) or $2.24 per diluted share and full fiscal year GAAP net income was $113.7 million or $2.65 per diluted share. As a comparison basis, GAAP income before taxes for the fourth quarter of fiscal 2016 was $20.2 million, as compared to $12.4 million, or a 63% increase over prior year.
     
  • On April 7, 2016, Abiomed announced that the Impella 2.5, Impella CP and Impella 5.0™ heart pumps received Food & Drug Administration (FDA) pre-market approval (PMA) for cardiogenic shock. In the setting of cardiogenic shock, the Impella therapy stabilizes a patient’s hemodynamics, unloads the left ventricle, perfuses the end organs and per the indication, allows for heart recovery.

“Our performance validates Impella as the new standard of care and Abiomed as one of the fastest growing, GAAP profitable, medical technology companies.  We have a long run-way for growth as today we estimate that we have penetrated only 5% of the total high risk patient population,” said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. “I am proud of our dedicated employees and grateful to our customers that have enabled our company to create a new era of medicine focused on the Field of Heart Recovery.  Fiscal 2017 is positioned to be a fantastic year as we continue to execute our plan with our exclusive regulatory approvals.”

FISCAL YEAR 2017 OUTLOOK
The Company is giving its fiscal year 2017 guidance for total revenues to be in the range of $430 million to $445 million, an increase of 30% to 35% over the prior year. The Company is also giving its fiscal year 2017 guidance for GAAP operating margin to be in the range of 18% to 20%.

EARNINGS CONFERENCE CALL DETAILS
The Company will host a conference call to discuss the results at 8 a.m. ET on Tuesday, May 3, 2016. The conference call releasing full quarterly results will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Michael Tomsicek, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538.  A replay of this conference call will be available beginning at 11 a.m. ET May 3, 2016 through 11:59 p.m. ET on May 5, 2016. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 75816370.

The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella 2.5, Impella 5.0, Impella LD, Recovering hearts. Saving lives., and Protected PCI are trademarks of Abiomed, Inc.

ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS 
This release includes forward-looking statements.  These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning.  These forward-looking statements address various matters. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.  Applicable risks and uncertainties include, among others, uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and the risks identified under the heading “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended March 31, 2015 and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2015, September 30, 2015 and December 31, 2015, each filed with the Securities and Exchange Commission, as well as other information the Company files with the SEC.  We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.  You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties.  The forward-looking statements in this press release speak only as of the date of this release and the Company undertakes no obligation to update or revise any of these statements.  Our business is subject to substantial risks and uncertainties, including those referenced above.  Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

For further information please contact: 

Ingrid Goldberg,
Director, Investor Relations
978-646-1590
ir@abiomed.com

Aimee Genzler
Director, Corporate Communications
978-646-1553
agenzler@abiomed.com

Abiomed, Inc. and Subsidiaries  
Consolidated Balance Sheets  
(Unaudited)  
(in thousands, except share data)  
           
    March 31, 2016   March 31, 2015  
           
ASSETS          
Current assets:          
Cash and cash equivalents   $ 48,231     $ 22,401    
Short-term marketable securities     163,822       109,557    
Accounts receivable, net     42,821       31,828    
Inventories     26,740       16,774    
Prepaid expenses and other current assets     6,778       4,479    
Total current assets     288,392       185,039    
Long-term marketable securities     1,000       13,996    
Property and equipment, net     23,184       9,127    
Goodwill     33,003       31,534    
In-process research and development     15,396       14,711    
Long-term deferred tax assets, net     58,534       80,306    
Other assets     4,422       3,654    
Total assets   $ 423,931     $ 338,367    
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable   $ 9,381     $ 10,389    
Accrued expenses     28,382       21,894    
Deferred revenue     8,778       7,036    
Total current liabilities     46,541       39,319    
Other long-term liabilities     220       183    
Contingent consideration     7,563       6,510    
Long-term deferred tax liabilities     832       795    
Total liabilities     55,156       46,807    
Commitments and contingencies          
Stockholders' equity:          
Class B Preferred Stock, $.01 par value              
Authorized - 1,000,000 shares; Issued and outstanding - none          
Common stock, $.01 par value     426       413    
Authorized - 100,000,000 shares; Issued - 43,973,119 shares at March 31, 2016 and 42,618,717 shares at March 31, 2015;          
Outstanding - 42,596,228 shares at March 31, 2016 and 41,335,773 shares at March 31, 2015          
Additional paid in capital     508,624       465,046    
Accumulated deficit     (99,075 )     (137,222 )  
Treasury stock at cost - 1,376,891 shares at March 31, 2016 and 1,282,944 shares at March 31, 2015     (26,660 )     (19,347 )  
Accumulated other comprehensive loss     (14,540 )     (17,330 )  
Total stockholders' equity     368,775       291,560    
Total liabilities and stockholders' equity   $ 423,931     $ 338,367    
Abiomed, Inc. and Subsidiaries  
Consolidated Statements of Operations  
(Unaudited)  
(in thousands, except per share data)  
                         
                         
  Three Months Ended 
March 31,
  Fiscal Years Ended 
March 31,
 
  2016   2015   2016   2015  
Revenue:                        
Product revenue $ 93,951   $   67,550     $ 329,520   $   229,950    
Funded research and development   6       7       23       361    
    93,957       67,557       329,543       230,311    
Costs and expenses:                        
Cost of product revenue   14,663       10,806       50,419       39,945    
Research and development   14,225       9,853       49,759       35,973    
Selling, general and administrative   45,256       34,535       164,261       125,727    
    74,144       55,194       264,439       201,645    
Income from operations   19,813       12,363       65,104       28,666    
Other income:                        
Investment income, net   186       68       395       196    
Other income (expense), net   228       (59 )     339       (97 )  
    414       9       734       99    
Income before income taxes   20,227       12,372       65,838       28,765    
Income tax provision (benefit)   9,229       (86,502 )     27,691       (84,923 )  
Net income $ 10,998   $   98,874     $ 38,147   $   113,688    
                         
Basic net income per share $ 0.26   $   2.40     $ 0.90   $   2.80    
Basic weighted average shares outstanding   42,463       41,168       42,204       40,632    
                         
Diluted net income per share $ 0.24   $   2.24     $ 0.85   $   2.65    
Diluted weighted average shares outstanding   45,112       44,049       44,895       42,858    
 

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38Pressemelding

Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia.  Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts

Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00Pressemelding

Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot

Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50Pressemelding

NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market.  I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30Pressemelding

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00Pressemelding

RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions   RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium  DR Capsules 49.3 mg  in the coming weeks   Esomeprazole Strontium  DR Capsules 49.3 mg  will be the third commercial GI product to be promoted by RedHill in the U.S.    RedHill's GI-focused sales force currently promotes two GI s

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressemelding

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom